Citations

Clear

95 citation(s) found for "Diamond, M P".

Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor–Positive/HER2-Negative Advanced or Metastatic Breast Cancer
Lim, Bora , Potter, David A. , Silverman, Paula , Haddad, Tufia C. , Forget, Frédéric, Awada, Ahmad , Canon, Jean‐Luc, Danso, Michael A., Lortholary, Alain , Bourgeois, Hugues , Tan-Chiu, Elizabeth, Vincent, Sylvie , Bahamón, Brittany, Neuwirth, Rachel, Leonard, E. Jane , Diamond, Jennifer R. , Silverman, Paula , Haddad, Tufia C , Awada, Ahmad , Bourgeois, Hugues , Vincent, Sylvie , Galinsky, Kevin J , Potter, David A , Salkeni, Mohamad Adham , Canon, Jean-Luc Re , Patel, Chirag Amrutlal , Lim, Bora

Mayo Clinic

Clinical Cancer Research | April 5, 2021 | Volume: 27 | Issue: 12 | Pages: 3329-3338

10.1158/1078-0432.ccr-20-4131 | PMID 33820779 Get It

Abstract Purpose: This open-label, multicenter, phase IB/II study evaluated sapanisertib, a dual inhibitor of mTOR kinase complexes 1/2, plus exemestane or fulvestrant in postmenopausal women with hormone receptor–positive (HR+)/HER2-negative (HER2−) advanced/metastatic breast cancer. Patients and Methods: Eligible patients had previously progressed on everolimus with exemestane/fulvestrant and received ≤3 (phase IB) or ≤1 (phase II) prior chemotherapy regimens. Patients received sapanisertib 3 to 5 mg every day (phase IB), or 4 mg every day (phase II) with exemestane 25 mg every day or fulvestrant 500 mg monthly in 28-day cycles. Phase II enrolled parallel cohorts based on prior response to everolimus. The primary objective of phase II was to evaluate antitumor activity by clinical benefit rate at 16 weeks (CBR-16). Results: Overall, 118 patients enrolled in phase IB (n = 24) and II (n = 94). Five patients in phase IB experienced dose-limiting toxicities, at sapanisertib doses of 5 mg every day (n = 4) and 4 mg every day (n = 1); sapanisertib 4 mg every day was the MTD in combination with exemestane or fulvestrant. In phase II, in everolimus-sensitive versus everolimus-resistant cohorts, CBR-16 was 45% versus 23%, and overall response rate was 8% versus 2%, respectively. The most common adverse events were nausea (52%), fatigue (47%), diarrhea (37%), and hyperglycemia (33%); rash occurred in 17% of patients. Molecular analysis suggested positive association between AKT1 mutation status and best treatment response (complete + partial response; P = 0.0262). Conclusions: Sapanisertib plus exemestane or fulvestrant was well tolerated and exhibited clinical benefit in postmenopausal women with pretreated everolimus-sensitive or everolimus-resistant breast cancer.
Declining Accuracy of the Traditional Diamond-Forrester Estimates of Pretest Probability of Coronary Artery Disease
Gibbons, Raymond J. , Miller, Todd D.

Mayo Clinic

JAMA Internal Medicine | March 8, 2021 | Volume: 181 | Issue: 5 | Pages: 579

10.1001/jamainternmed.2021.0171 | PMID 33683301 Get It

Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome
LaRovere, Kerri L. , Riggs, Becky J. , Young, Cameron C. , Newhams, Margaret M. , Maamari, Mia , Walker, Tracie C. , Singh, Aalok R. , Dapul, Heda , Hobbs, Charlotte V. , McLaughlin, Gwenn E., Maddux, Aline B. , Clouser, Katharine N. , Rowan, Courtney M. , McGuire, John K. , Gertz, Shira J. , Muñoz, Álvaro Coronado , Irby, Katherine , Levy, Emily R. , Staat, Mary Allen , Feldstein, Leora R. , Halasa, Natasha , Hall, Mark W. , Kong, Michele , Carroll, Christopher L. , Schuster, Jennifer E. , Doymaz, Sule , Loftis, Laura L. , Tarquinio, Keiko M. , Babbitt, Christopher , Nofziger, Ryan A. , Kleinman, Lawrence C. , Keenaghan, Michael , Spinella, Philip C. , Hume, Janet R. , Wellnitz, Kari , Mack, Elizabeth H. , Flori, Heidi R. , Patel, Manish M. , Randolph, Adrienne G. , Investigators, Overcoming COVID-19, Name, First Name and Middle Initial Last, Gaspers, Mary Glas , Typpo, Katri , Sanders, Ronald C., Schwarz, Adam J. , Harvey, Helen , Mourani, Peter M. , Coates, Bria M. , Bhoojhawon, Guru , Havlin, Kevin , Sullivan, Janice E, Bradford, Tamara T. , Lipton, Susan V., Chen, Sabrina , Kücükak, Suden, Carroll, Ryan W. , Fernandes, Neil D. , Yager, Phoebe H. , Marohn, Kimberly L, Heidemann, Sabrina M. , Cullimore, Melissa L. , Horwitz, Steven M. , Walsh, Rowan, Soma, Vijaya L, Gillen, Jennifer , Zackai, Sheemon, Ackerman, Kate G. , Cholette, Jill M., Hymes, Saul , Overby, Philip , Schwartz, Stephanie P. , Lansell, Amanda , Koncicki, Monica L. , Carcillo, Joseph A. , Bowens, Cindy , Crandall, Hillary , Smith, Lincoln , Cengiz, Pelin , Levy, Emily R , Young, Cameron C , Randolph, Adrienne G , Spinella, Philip C , Kong, Michele , Hume, Janet R , Hobbs, Charlotte V , Maddux, Aline B , Staat, Mary A , Gertz, Shira J , Schwartz, Stephanie P , Hymes, Saul R , Poussaint, Tina Young , Son, Mary Beth F. , Fitzgerald, Julie C. , Shein, Steven L. , Thomas, Neal J. , Tenforde, Mark W. , Giuliano, John S. , Cvijanovich, Natalie Z , Michelson, Kelly Nicole , Investigators, Overcoming COVID-19, Zinter, Matt S. , Montgomery, Vicki , Sullivan, Janice E, Bembea, Melania M. , Graciano, Ana Lía , Newburger, Jane W. , Marohn, Kimberly L, McCulloh, Russell J. , Li, Simon , Ratner, Adam J. , Harwayne‐Gidansky, Ilana , Fink, Ericka L. , Kimura, Dai

Mayo Clinic

JAMA Neurology | March 5, 2021 | Volume: 78 | Issue: 5 | Pages: 536

10.1001/jamaneurol.2021.0504 | PMID 33666649 Get It

Black Women Are More Likely Than White Women to Schedule a Uterine-Sparing Treatment for Leiomyomas
Wegienka, Ganesa , Nicholson, Wanda K. , Zhang, Shuaiqi , Li, Fan , Thomas, Laine , Spies, James B. , Venable, Sateria, Laughlin-Tommaso, Shannon K., Anchan, Raymond M. , Maxwell, G. Larry , Marsh, Erica E. , Vines, Anissa I. , Jacoby, Vanessa L. , Laughlin-Tommaso, Shannon, Diamond, M P , Stewart, Elizabeth A. , Myers, Evan R. , Wise, Lauren Anne , Wallace, Kedra

Mayo Clinic

Journal of Women's Health | February 1, 2021 | Volume: 30 | Issue: 3 | Pages: 355-366

10.1089/jwh.2020.8634 | PMID 33524308 Get It

Background: To evaluate differences in the proportion of uterine fibroid (UF) treatments that are uterine-sparing between Black women and White women and identify factors that could explain disparities. Methods: Women at age 18–54 years who were enrolled from 10 clinical sites in the United States into the Comparing Options for Management: Patient-Centered Results for UFs (COMPARE-UF) treatment registry completed questionnaires before their UF procedure. UF symptoms and quality of life were assessed by questionnaires. Details on UF imaging and treatment (hysterectomy, myomectomy, or uterine artery embolization [UAE]) were collected from each patient's medical record. Random-effects logistic regression was used to assess the association between race and the odds of having a uterine-sparing procedure versus hysterectomy. Subgroup analyses compared each uterine-sparing procedure with hysterectomy. Results: In this cohort of 1141 White women and 1196 Black women, Black women tended to be younger (median 41.0 vs. 42.0 years) and report worse symptoms, pain, and function on every scale compared with White women. Black women were more likely to have had a prior UF treatment compared with White women (22.8% vs. 14.6%). White women had more hysterectomies (43.6% vs. 32.2%) and myomectomies (50.9% vs. 50.2%) versus Black women. Black women had more UAEs (15.1% vs. 4.7%) than White women. After adjusting for clinical site and other variables, Black women had greater odds than White women of having a myomectomy (odds ratio [OR] = 2.41, 95% confidence interval [CI] = 1.63–3.56) or a UAE versus hysterectomy (OR = 4.24, 95% CI = 2.41–7.46). Conclusion: In these participants, Black women were more likely to schedule a uterine-sparing UF treatment and a nonsurgical UF treatment than their White counterparts; this may not be true for all women. Longer comparative effectiveness studies are needed to inform women about the durability of UF treatments. Greater understanding of factors influencing treatment selection is needed as are studies that include women without access to tertiary care centers. Clinical Trial Registration: Clinicaltrials.gov, NCT02260752 (enrollment start: November 2015).
Next-Generation Diamond Electrodes for Neurochemical Sensing: Challenges and Opportunities
Purcell, Erin K. , Becker, Michael , Guo, Yue , Hara, Seth A. , Ludwig, Kip A. , McKinney, Collin , Monroe, Elizabeth, Rechenberg, Robert, Rusinek, Cory A. , Saxena, Akash , Siegenthaler, James R. , Sortwell, Caryl E. , Witt, Suzanne E. , McKinney, Collin J , Trevathan, James K , Witt, Suzanne , Ludwig, Kip A , Monroe, Elizabeth, Thompson, Cort H. , Trevathan, James K. , Li, Wen

Mayo Clinic

Micromachines | January 26, 2021 | Volume: 12 | Issue: 2 | Pages: 128

10.3390/mi12020128 | PMID 33530395 Get It

Carbon-based electrodes combined with fast-scan cyclic voltammetry (FSCV) enable neurochemical sensing with high spatiotemporal resolution and sensitivity. While their attractive electrochemical and conductive properties have established a long history of use in the detection of neurotransmitters both in vitro and in vivo, carbon fiber microelectrodes (CFMEs) also have limitations in their fabrication, flexibility, and chronic stability. Diamond is a form of carbon with a more rigid bonding structure (sp3-hybridized) which can become conductive when boron-doped. Boron-doped diamond (BDD) is characterized by an extremely wide potential window, low background current, and good biocompatibility. Additionally, methods for processing and patterning diamond allow for high-throughput batch fabrication and customization of electrode arrays with unique architectures. While tradeoffs in sensitivity can undermine the advantages of BDD as a neurochemical sensor, there are numerous untapped opportunities to further improve performance, including anodic pretreatment, or optimization of the FSCV waveform, instrumentation, sp2/sp3 character, doping, surface characteristics, and signal processing. Here, we review the state-of-the-art in diamond electrodes for neurochemical sensing and discuss potential opportunities for future advancements of the technology. We highlight our team’s progress with the development of an all-diamond fiber ultramicroelectrode as a novel approach to advance the performance and applications of diamond-based neurochemical sensors.
Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication‐overuse headache: Subgroup analysis of PROMISE‐2
Marmura, Michael J. , Tepper, Stewart J. , Cowan, Robert P. , Starling, Amaal J. , Diamond, Merle L., Hirman, Joe, Mehta, Lahar, Brevig, Thomas, Sperling, Bjørn, Cady, Roger , Marmura, Michael J , Cowan, Robert P , Diener, Hans‐Christoph

Mayo Clinic

Headache: The Journal of Head and Face Pain | December 14, 2020 | Volume: 61 | Issue: 1 | Pages: 125-136

10.1111/head.14036 | PMID 33314079 Get It

Abstract Objective To evaluate the efficacy, tolerability, and safety of eptinezumab 100 and 300 mg compared with placebo in patients with the dual diagnosis of chronic migraine (CM) and medication‐overuse headache (MOH). Background Eptinezumab, a humanized monoclonal antibody targeting calcitonin gene‐related peptide, may be effective for treating patients with a dual diagnosis of CM and MOH. Methods PROMISE‐2 (NCT02974153) was a double‐blind, randomized, placebo‐controlled, phase 3 study that comprised a screening visit, a 28‐day pretreatment period, and a 32‐week study duration. Patients in this exploratory analysis of a prespecified subgroup had confirmed diagnoses of both CM and MOH at screening. Patients were randomly assigned to receive intravenous eptinezumab 100, 300 mg, or placebo every 12 weeks. Efficacy outcomes included mean changes from baseline in monthly migraine days (MMDs) during weeks 1–12, migraine responder rates at week 12, and percentages of patients below International Classification of Headache Disorders thresholds for CM and MOH over weeks 1–24. Results There were 431 patients who were diagnosed with CM and MOH as specified in the protocol and received eptinezumab 100 mg ( n = 139), 300 mg ( n = 147), or placebo ( n = 145). During the baseline period, these patients experienced an average of 16.7 migraine days across treatment arms. Over weeks 1–12, eptinezumab‐treated patients experienced greater reductions from baseline in MMDs than placebo patients (100 mg, change from baseline = −8.4, difference from placebo [95% confidence interval (CI)] = −3.0 [−4.56, −1.52], p < 0.0001 vs. placebo; 300 mg, change from baseline = −8.6, difference from placebo [95% CI] = −3.2 [−4.66, −1.78], p < 0.0001 vs. placebo; placebo, −5.4). Compared with placebo, more eptinezumab‐treated patients were ≥50% migraine responders (100 mg, 84/139 [60.4%]; 300 mg, 91/147 [61.9%]; placebo, 50/145 [34.5%]) or ≥75% responders (100 mg, 38/139 [27.3%]; 300 mg, 44/147 [29.9%]; placebo, 21/145 [14.5%]) over weeks 1–12. Therapeutic benefits with eptinezumab were observed from day 1 after dosing, and improvements were sustained with an additional dose. For the full 24‐week treatment period, 71/139 (51.1%), 80/147 (54.4%), and 47/145 (32.4%) of 100, 300 mg, and placebo‐treated patients, respectively, were below CM thresholds, and of the patients who provided sufficient acute medication data, 47/93 (50.5%), 53/107 (49.5%), and 26/96 (27.1%), respectively, were below medication‐overuse thresholds. Conclusions In patients diagnosed with both CM and MOH, eptinezumab treatment resulted in greater reductions in MMDs, higher responder rates, and fewer patients meeting CM and MOH criteria, thus demonstrating the efficacy and clinical utility of eptinezumab in this patient population.
Returning Athletes Back to High School Sports in the COVID-19 Era: Preparing for the Fall
Asif, Irfan M. , Chang, Cindy J. , Diamond, Alex B., Zaremski, Jason L. , Raukar, Neha, Raukar, Neha P.

Mayo Clinic

Sports Health: A Multidisciplinary Approach | August 20, 2020 | Volume: 12 | Issue: 6 | Pages: 518-520

10.1177/1941738120953851 | PMID 32816648 Get It

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era
Goyal, Gaurav , Heaney, Mark , Collin, Matthew , Cohen‐Aubart, Fleur , Durham, Benjamin H. , Hershkovitz‐Rokah, Oshrat , Girschikofsky, Michael , Jacobsen, Eric D. , Toyama, Kazuhiro, Goodman, Aaron M. , Hendrie, Paul C. , Estrada‐Veras, Juvianee , Shpilberg, Ofer , Abdo, André , Kurokawa, Mineo , Mazor, Roei David , Jankú, Filip , Haroche, Julien , Goyal, Guarav , Collin, Matthew , Hershkovitz-Rokah, Oshrat , Mazor, Roei D , Durham, Benjamin , Vaglio, Augusto , Cao, Xin-Xin , Dagna, Lorenzo , McClain, Kenneth L. , Picarsic, Jennifer , Go, Ronald S. , Diamond, Eli L.

Mayo Clinic

Blood | March 18, 2020 | Volume: 135 | Issue: 22 | Pages: 1929-1945

10.1182/blood.2019003507 | PMID 32187362 Get It

Abstract Erdheim-Chester disease (ECD) is a rare histiocytosis that was recently recognized as a neoplastic disorder owing to the discovery of recurrent activating MAPK (RAS-RAF-MEK-ERK) pathway mutations. Typical findings of ECD include central diabetes insipidus, restrictive pericarditis, perinephric fibrosis, and sclerotic bone lesions. The histopathologic diagnosis of ECD is often challenging due to nonspecific inflammatory and fibrotic findings on histopathologic review of tissue specimens. Additionally, the association of ECD with unusual tissue tropism and an insidious onset often results in diagnostic errors and delays. Most patients with ECD require treatment, except for a minority of patients with minimally symptomatic single-organ disease. The first ECD consensus guidelines were published in 2014 on behalf of the physicians and researchers within the Erdheim-Chester Disease Global Alliance. With the recent molecular discoveries and the approval of the first targeted therapy (vemurafenib) for BRAF-V600–mutant ECD, there is a need for updated clinical practice guidelines to optimize the diagnosis and treatment of this disease. This document presents consensus recommendations that resulted from the International Medical Symposia on ECD in 2017 and 2019. Herein, we include the guidelines for the clinical, laboratory, histologic, and radiographic evaluation of ECD patients along with treatment recommendations based on our clinical experience and review of literature in the molecular era.
Frequent Clinical Overlap of Histiocytic Neoplasms and WHO-Classified Myeloid Malignancies Leads to Functional Insights into the Cell-of-Origin of Histiocytoses
Özkaya, Neval , Ganzel, Chezi , Hyman, David M. , Rampal, Raajit K. , Lemoine, François M., Amoura, Zahir , Haroche, Julien , Durham, Benjamin H. , Yoshimi, Akihide , Papo, Matthias , Chung, Young Rock , Doǧan, Ahmet , Park, Christopher Y. , Roos-Weil, Damien , Bernard, Olivier , Diamond, Eli L. , Emile, Jean‐François , Abdel‐Wahab, Omar

Mayo Clinic

Blood | October 11, 2019 | Volume: 128 | Issue: 22 | Pages: 951-951

10.1182/blood.v128.22.951.951 Get It

Abstract The identification of mutations in BRAFV600E and other kinases in systemic histiocytoses changed our understanding of the pathophysiology of these disorders from inflammatory non-malignant conditions to clonal disorders driven by altered MAP kinase signaling. In addition, BRAFV600E mutations have recently been noted in bone marrow (BM) CD34+ cells of patients with Langerhans Cell Histiocytosis (LCH), suggesting that LCH represents a clonal disorder arising from hematopoietic stem/progenitor cells (HSPCs). However, it is unknown if HSPCs from LCH or other histiocytoses patients can functionally give rise to these disorders. Moreover, whether or not patients with histiocytosis have additional hematological disorders related to the presence of HSPC-based mutations is unclear. Here we attempted to understand the spectrum of hematological disorders in patients with histiocytoses and the cell-of-origin of histiocytic neoplasms by functionally analyzing HSPCs from histiocytoses patients. We first analyzed a multicenter cohort of 190 adult histiocytoses patients. This unexpectedly identified a high frequency of patients with a co-existing myeloid malignancy. Of the 190 patients, 9.5% (18/190) were diagnosed with Erdheim-Chester Disease (ECD) and/or LCH concomitantly with a classic MPN (3.7%; 7/190), MPN/MDS overlap (4.7%; 9/190), or MDS (1.1%; 2/190) (Figure). This clinical observation was confirmed by detection of co-existing histiocytoses-associated kinase mutations (including BRAF, MAP2K1, NRAS, or KRAS mutations) with JAK2 or CALR mutations, as well as other mutations recurrently found in myeloid malignancies (such as IDH1/2, ASXL1, and TET2 mutations (Figure)). These data therefore reveal a heretofore-unrecognized clinical overlap of adult-onset systemic histiocytoses and WHO-classified myeloid malignancies while further highlighting the possibility of an aberrant HSPC origin for histiocytic neoplasms. In most cases, the BRAF/MAP2K1/RAS mutation predominated in the histiocytic lesion while the JAK2/CALR mutation predominated in the BM/peripheral blood suggesting likely distinct clones driving each clinical condition. Next, to test the self-renewal and differentiation capacity of HSPCs from histiocytoses patients, CD34+ cells were purified from 8 patients including 6 with ECD or LCH plus a concomitant myeloid neoplasm, and 2 with ECD alone. 0.1-0.8x106 CD34+ cells from each patient were transplanted by intrafemoral injection into sublethally irradiated NOD/SCID IL2Rγ transgenic human GM-CSF, IL-3, and SCF expressing (NSG-SGM3) mice. Human engraftment was monitored by monthly flow cytometric analysis of peripheral blood until mice became moribund. Thereafter, animals were sacrificed and tissues were analyzed using flow cytometry, histology, immunohistochemistry, and sequencing analyses to detect driver mutations identified in the histiocytosis/co-occurring myeloid neoplasm. Successful engraftment of human myeloid cells was verified in grafts generated from 2/8 patients after a mean of 90 days (range: 60-120 days). This included lethal engraftment of KRAS-mutated ECD patient cells at 90 days manifested by infiltration of human hCD45+ cells co-expressing human myeloid and monocyte lineage markers hCD33 and hCD14 in the bone marrow, spleen, liver, lung, and kidney (Figure). Immunostains revealed that tissues were infiltrated by an hCD45+hCD163+hCD68+ population of foamy histiocytes, characteristic of ECD (Figure). Furthermore, genomic analysis of DNA from the engrafted animals BM and spleen revealed the same KRASG12S mutation found in the donor patients ECD lesion. Engraftment of a patient diagnosed with concomitant BRAFV600E-mutant ECD and ASXL1/TET2-mutant CMML was seen at 60 days. In this case, however, only engraftment of human CMML was detected without evidence of the BRAFV600E-mutant ECD component. This study suggests that adult histiocytic neoplasms frequently co-occur with other myeloid neoplasms. Moreover, histiocytosis disease-driver mutations are present in the CD34+ HSPCs, which we show for the first time can initiate disease that resembles human histiocytosis in a patient-derived xenograft. Importantly, however, even though the CD34+ compartment gives rise to both the histiocytic and myeloid neoplasm disease component, each disease is likely initiated by distinct precursors. Figure. Figure. Disclosures No relevant conflicts of interest to declare.
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms
Haroche, Julien , Yao, Zhan, Ma, Jing , Cohen‐Aubart, Fleur , Micol, Jean‐Baptiste , Walsh, Michael P. , Sylvester, Brooke E., Aminova, Olga, Heguy, Adriana , Zappile, Paul, Dalton, James , Ellison, David W. , Estrada‐Veras, Juvianee , Gahl, William A. , Stephens, Phil , Miller, Vincent A. , Ross, Jeffrey , Ali, Siraj , Hyman, David M. , Baselga, José, Jankú, Filip , Taylor, Barry S. , Amoura, Zahir , Rampal, Raajit K. , Rosen, Neal , Durham, Benjamin H. , Diamond, Eli L. , Parikh, Sameer A. , Choi, John , Kim, Eun Hee , Lee, Stanley Chun-Wei , Gao, Yijun , Campbell, Patrick , Dolgalev, Igor , Nakitandwe, Joy , Lacouture, Mario E. , Ross, Jeffrey, Héritier, Sébastien , Donadieu, Jean , Solit, David B. , Park, Christopher Y. , Doǧan, Ahmet , Emile, Jean‐François , Gruber, Tanja Andrea , Abdel‐Wahab, Omar

Mayo Clinic

Blood | October 10, 2019 | Volume: 126 | Issue: 23 | Pages: 481-481

10.1182/blood.v126.23.481.481 Get It

Abstract Histiocytic neoplasms are clonal, hematopoietic disorders characterized by an accumulation of abnormal monocyte-derived dendritic cells or macrophages in Langerhans Cell (LCH) and non-Langerhans (non-LCH) histiocytoses, respectively. The discovery of the BRAF V600E mutation in ~50% of patients with LCH and the non-LCH Erdheim-Chester Disease (ECD) provided the first molecular target in these patients and novel insights into the pathogenesis of these disorders. However, recurrent mutations in the majority of the ~50% of BRAF V600E-wild type patients with non-LCH are unknown. Moreover, recurrent mutations outside of the MAP kinase pathway are undefined throughout histiocytic neoplasms. To address these issues, we performed whole exome sequencing (WES) of frozen biopsies from 24 patients with LCH (n=10) or ECD (n=14) paired with peripheral blood mononuclear cells. 13/24 patients also underwent RNA sequencing (RNA-seq). All mutations in activating kinases were validated by droplet-digital PCR, while targeted-capture next-generation sequencing validated all others. Both adult (n=18; n=2 with LCH) and pediatric cases (n=9; n=8 with LCH) were included. Using combined WES/RNA-seq, activating kinase alterations were identified in 100% of patients. In LCH, 60% and 40% had BRAF V600E and MAP2K1 mutations, respectively. In non-LCH 51%, 14%, 14%, and 7% were BRAFV600E, ARAF, MAP2K1, and NRAS mutant (Fig1A). Overall, a mean of 7 non-synonymous mutations per adult patient was identified (range 1-22) compared with 5 mutations per pediatric patient (range 4-9; p =ns). Mutations affecting diverse cellular processes were found to co-exist with kinase mutations including mutations in epigenetic modifiers and the p38/MAPK pathway. In addition to kinase point mutations, RNA-seq identified recurrent, in-frame kinase fusions-a first for these disorders. All identified fusions were validated using FISH and RT-PCR. This includes novel fusions in BRAF (RNF11-BRAF and CLIP2-BRAF), as well as therapeutically important fusions in ALK (2 separate KIF5B-ALK fusions) and NTRK1 (LMNA-NTRK1;Fig1B). Expression of each fusion in Ba/F3 cells conferred cytokine-independent growth. Importantly, the BRAF fusions were found to be sensitive to MEK inhibition but resistant to vemurafenib while the ALK fusions conferred sensitivity to the ALK inhibitors crizotinib or alectinib. We next interrogated a validation cohort of 37 BRAF V600E-wild type, non-LCH, formalin-fixed, paraffin-embedded tissue samples using targeted mutational profiling for MAP2K1, ARAF, NRAS, KRAS, and PIK3CA. This revealed activating mutations in MAP2K1 (32%; n=12), NRAS (16%; n=6), KRAS (11%; n=4), PIK3CA (8%; n=3), and ARAF (3%; n=1). Three of the investigated non-LCH patients with refractory disease and progressive organ dysfunction were treated with targeted therapies based on the discovery of novel kinase alterations described above. Treatment of 2 refractory MAP2K1- mutant, non-LCH patients with MEK inhibitors (trametinib or cobimetinib) resulted in dramatic clinical improvement (Fig1C). Both patients have been maintained on MEK inhibitor single-agent therapy with a sustained clinical response for >100 days. Further evidence of effective targeted inhibition was found in a refractory ECD patient carrying an ARAF S214A mutation. This patient failed to respond to 3 lines of prior therapies and suffered near blindness due to disease infiltration in the retina and optic nerves. Given a recent report of complete response to sorafenib in a lung cancer patient with an ARAF S214C mutation, we initiated sorafenib. Within 12 weeks, there was improvement in the patientÕs eyesight and decreased infiltrative disease, coinciding with >50% decrease in mutant ARAF DNA in plasma cell-free DNA. Whole exome and transcriptome sequencing identified activating kinase mutations or translocations in all patients with the common downstream effect of activating the MAPK pathway. The preliminary, dramatic, clinical efficacy observed with use of MEK and RAF inhibitors in MAP2K1 - and ARAF-mutated, non-LCH patients further supports the central role of targeting the MAPK pathway in these tumors. The discovery of the discussed mutations and fusions in diverse kinases provides critical new insights into the genetic events central to a spectrum of adult and pediatric histiocytic neoplasms. Figure 1. Figure 1. Disclosures Off Label Use: This abstract describes use of MEK inhibitors (both tremetinib and cobimetinib) as well as sorafenib for MEK1 and ARAF mutant histiocytosis. . Stephens:Foundation Medicine, Inc.: Employment, Equity Ownership. Miller:Foundation Medicine, Inc.: Employment, Equity Ownership. Ross:Foundation Medicine Inc.: Employment. Ali:Foundation Medicine Inc.: Employment. Hyman:Chugai Pharma: Consultancy; Biotherapeutics: Consultancy; Atara: Consultancy, Honoraria.